期刊文献+

左炔诺孕酮T形宫内节育器治疗子宫腺肌病46例分析 被引量:33

Effectiveness of Mirena on Treatment of Adenomyosis:Analysis of 46 Cases
在线阅读 下载PDF
导出
摘要 目的:探讨宫腔内放置含左炔诺孕酮的T形宫内节育器(曼月乐)治疗子宫腺肌病的疗效。方法:选择46例患子宫腺肌病的已育妇女,选择月经周期第5—8天放置左炔诺孕酮T形宫内节育器。分别在放置前、放置后3个月、12个月观察其月经量、血红蛋白、痛经、子宫体积及血清中FSH、LH、E2水平的变化。结果:放置左炔诺孕酮T形宫内节育器后,患者的月经量较放置前明显减少(P〈0.01),18例患者出现时间长短不等的闭经;血红蛋白较放置前无明显增加(P〉0.05);痛经明显减轻(P〈0.01);子宫体积较放置前明显缩小(P〈0.05);血清FSH、LH、E2水平较放置前无明显变化(P〉0.05)。结论:宫腔内放置左炔诺孕酮T形宫内节育器能明显减轻患者的临床症状,对卵巢功能无明显影响,能有效地提高患者的生活质量,有很好的临床应用价值。 Objective: To evaluate the effects and the side-effects of Mirena on treatment of adenomyosis. Methcds:Mirana were inserted into the 46 gravida cases with adenomyosis, on the 5 - 8th day of menstrual cycle.The menstrual blood loss, dysmenorrhoea scores, hemoglobin, uterine volume, and the levels of serum FSH, LH, E2 were recorded before insertion,threa months and 12 months after insertion respectively. Results.After insertion of Mirena, the menstrual blood loss significantly decreased ( P〈 0.01 ) ;Amenorrhoea occurred in 18 patients with different duration. But the level of Hemoglobin had no significantly increased ( P 〉 0.05). The dysmenorrhoea scores became lower,evan vanished in some cases.The uterine volume decreased also ( P〈 0.05) .The serum FSH, LH,and E2 levels had no marked change ( P 〉 0.05). Concluslons. Mirena inserting inside uterine cavity can significantly alleviate the clinical symptoms of adenomyosis with no effect on ovarian function. Moreover, it can improve the patients' living quality,and is quite promising in the clinical application.
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2006年第12期742-744,共3页 Journal of Practical Obstetrics and Gynecology
关键词 子宫腺肌痛 左炔诺孕酮 宫内节育器 Adanomyosis Levonorgestrel(LNG) Intrauterine contraceptive device(IUD)
  • 相关文献

参考文献5

二级参考文献23

  • 1Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynecol Forum, 1998, 3(1): 11-14.
  • 2Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine system. Semi Reprod Med, 2001, 19(4): 355-363.
  • 3Zalel Y, Shulman A, Lidor A, et al. The local progestational efffect of the levonorgestrel-releasing intrauterine system: a sonographic and Doppler flow study. Hum Reprod, 2002, 17(11):2878-2880.
  • 4Guillebaud .I. The levnorgestrel intrauterine systemL: a clinical perspective from the UK. Ann N Y Acad Sci, 2003, 997(2): 185-193.
  • 5Backman T, Huhtala S, Luoto R, et al. Advance information improves improves user satisfaction with the levonorgestrel intrauterine system.Obstet Gynecol, 2002, 99(4): 608-613.
  • 6French R, Cowan F, Mansour D, et al. Hormonally impregnated intrauterine systems(IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev, 2001,(2):CD001776.
  • 7Backman T, Rauramo I, Huhtala S, et al. Pregancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol, 2004, 190(1):50-54.
  • 8Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf, 2004, 27(2):75-90.
  • 9Xiao BL, Wu SC, Chong J, et al. Therapeutic effects of the lenonorgestrelrelesing intrauterina system in the treatment of idiopathic menorrhagia. Fertil Steril, 2003, 79(4):963-969.
  • 10Barrington JW, Arunkalivanan AS, Avdek-Fattah M. Compariso between the levonorgestrel intrauterine system (LNG-IUS)and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol, 2003, 108(1):72-74.

共引文献175

同被引文献224

引证文献33

二级引证文献177

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部